BD adds informatics option to its COVID testing platforms
Healthcare providers who use the Becton Dickinson (NYSE:BDX) BD Veritor Plus and BD Max COVID-19 testing platforms have a new informatics option.
BD announced today that it has launched new reporting capabilities for COVID-19 data, enabling its BD Synapsys informatics to generate scheduled reports. BD Veritor Plus is a portable instrument designed to deliver SARS-CoV-2 antigen test results in approximately 15 minutes, and the molecular diagnostic BD Max platform can return results in two to three hours. Both hold FDA emergency use authorizations.
The BD Synapsys software’s new capabilities allow customers to create general-purpose reports with COVID-19 data and also offers configured reporting capabilities, which allow customers in the U.S. to generate reports in accordance with the U.S. Coronavirus Aid, Relief, and Economic Security (CARES) Act. The CARES Act requires COVID-19 testing facilities to report testing data to local and federal health authorities daily, including the number of tests performed, results and key patient demographics. Additional configured reports can be developed, as needed.
“BD Synapsys Informatics unifies instrument-read COVID-19 test results from the BD Veritor and BD MAX systems,” said Rajeev Sehgal, director of informatics for BD Integrated Diagnostics Solutions, in a news release. “The solution’s new encrypted reporting capabilities reduce the burden associated with manual reporting. This empowers customers to focus on what matters most: Caring for their patients.”
“Timely, accurate reporting allows public health officials to monitor the spread of COVID-19,” added Troy Hopps, BD’s business group leader for point-of-care diagnostics. “For COVID-19 testing facilities — including labs, hospitals and nursing homes — the BD Synapsys informatics solution’s new reporting capabilities, supported by secure connectivity, simplifies the process of reporting test results to public health authorities.”